{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:33:25Z","timestamp":1783578805212,"version":"3.55.0"},"reference-count":158,"publisher":"National Institute for Health and Care Research","issue":"56","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/06\/04"],"award-info":[{"award-number":["15\/06\/04"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA\u00ae<\/jats:sup>, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX\u00ae<\/jats:sup>, Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA\u00ae<\/jats:sup>, UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the clinical effectiveness and cost-effectiveness of CZP and SEC for treating active PsA in adults in whom DMARDs have been inadequately effective.<\/jats:p><\/jats:sec>Design<\/jats:title>Systematic review and economic model.<\/jats:p><\/jats:sec>Data sources<\/jats:title>Fourteen databases (including MEDLINE and EMBASE) were searched for relevant studies from inception to April 2016 for CZP and SEC studies; update searches were run to identify new comparator studies.<\/jats:p><\/jats:sec>Review methods<\/jats:title>Clinical effectiveness data from randomised controlled trials (RCTs) were synthesised using Bayesian network meta-analysis (NMA) methods to investigate the relative efficacy of SEC and CZP compared with comparator therapies. A de novo model was developed to assess the cost-effectiveness of SEC and CZP compared with the other relevant comparators. The model was specified for three subpopulations, in accordance with the NICE scope (patients who have taken one prior DMARD, patients who have taken two or more prior DMARDs and biologic-experienced patients). The models were further classified according to the level of concomitant psoriasis.<\/jats:p><\/jats:sec>Results<\/jats:title>Nineteen eligible RCTs were included in the systematic review of short-term efficacy. Most studies were well conducted and were rated as being at low risk of bias. Trials of SEC and CZP demonstrated clinically important efficacy in all key clinical outcomes. At 3 months, patients taking 150\u2009mg of SEC [relative risk (RR) 6.27, 95% confidence interval (CI) 2.55 to 15.43] or CZP (RR 3.29, 95% CI 1.94 to 5.56) were more likely to be responders than patients taking placebo. The NMA results for the biologic-naive subpopulations indicated that the effectiveness of SEC and CZP relative to other biologics and each other was uncertain. Limited data were available for the biologic-experienced subpopulation. Longer-term evidence suggested that these newer biologics reduced disease progression, with the benefits being similar to those seen for older biologics. The de novo model generated incremental cost-effectiveness ratios (ICERs) for three subpopulations and three psoriasis subgroups. In subpopulation 1 (biologic-naive patients who had taken one prior DMARD), CZP was the optimal treatment in the moderate\u2013severe psoriasis subgroup and 150\u2009mg of SEC was optimal in the subgroups of patients with mild\u2013moderate psoriasis or no concomitant psoriasis. In subpopulation 2 (biologic-naive patients who had taken two or more prior DMARDs), etanercept (ETN; ENBREL\u00ae<\/jats:sup>, Pfizer Inc., New York City, NY, USA) is likely to be the optimal treatment in all subgroups. The ICERs for SEC and CZP versus best supportive care are in the region of \u00a320,000\u201330,000 per quality-adjusted life-year (QALY). In subpopulation 3 (biologic-experienced patients or patients in whom biologics are contraindicated), UST is likely to be the optimal treatment (ICERs are in the region of \u00a321,000\u201327,000 per QALY). The optimal treatment in subpopulation 2 was sensitive to the choice of evidence synthesis model. In subpopulations 2 and 3, results were sensitive to the algorithm for Health Assessment Questionnaire-Disability Index costs. The optimal treatment is not sensitive to the use of biosimilar prices for ETN and infliximab (REMICADE\u00ae<\/jats:sup>, Merck Sharp & Dohme, Kenilworth, NJ, USA).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>SEC and CZP may be an effective use of NHS resources, depending on the subpopulation and subgroup of psoriasis severity. There are a number of limitations to this assessment, driven mainly by data availability.<\/jats:p><\/jats:sec>Future work<\/jats:title>Trials are needed to inform effectiveness of biologics in biologic-experienced populations.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42016033357.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta21560","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T15:09:10Z","timestamp":1507129750000},"page":"1-326","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"21","author":[{"given":"Mark","family":"Corbett","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Chehadah","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousumi","family":"Biswas","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirimon","family":"Moe-Byrne","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Harden","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ho","sequence":"additional","affiliation":[{"name":"The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children\u2019s University Hospitals Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2017,10]]},"reference":[{"key":"key20171003154212591_ref1-bib1","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-7234-3691-1.00070-2","volume-title":"Spondyloarthritis","author":"Reveille","year":"2013"},{"key":"key20171003154212591_ref1-bib2","volume-title":"What is Psoriatic Arthritis?","author":"Arthritis Foundation"},{"key":"key20171003154212591_ref1-bib3","volume-title":"Psoriatic Arthritis","author":"Emery","year":"2013"},{"key":"key20171003154212591_ref1-bib4","volume-title":"Psoriatic Arthritis","author":"Shiel","year":"2015"},{"key":"key20171003154212591_ref1-bib5","first-page":"127","article-title":"Psoriatic arthritis (PSA) \u2013 an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"key20171003154212591_ref1-bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"key":"key20171003154212591_ref1-bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-4362.2003.01449.x","article-title":"Newly available treatments for psoriatic arthritis and their impact on skin psoriasis","volume":"42","author":"Galadari","year":"2003","journal-title":"Int J Dermatol"},{"key":"key20171003154212591_ref1-bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0190-9622(03)01145-9","article-title":"Evaluation and management of psoriatic arthritis: the role of biologic therapy","volume":"49","author":"Ruderman","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"key20171003154212591_ref1-bib9","doi-asserted-by":"crossref","first-page":"e0123582","DOI":"10.1371\/journal.pone.0123582","article-title":"A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis","volume":"10","author":"Michelsen","year":"2015","journal-title":"PLOS ONE"},{"key":"key20171003154212591_ref1-bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/annrheumdis-2013-eular.2000","article-title":"High economic burden of moderate to severe psoriatic arthritis on paid work and household productivity: baseline results from the RAPID-PsA study (poster SAT0275)","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis","volume":"52","author":"Mease","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"key20171003154212591_ref1-bib12","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib14","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.22800","article-title":"Improved survival in psoriatic arthritis with calendar time","volume":"56","author":"Ali","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib15","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","article-title":"Classification and diagnostic criteria for psoriatic arthritis","volume":"64","author":"Helliwell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib17","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib18","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib19","volume-title":"Referral Pathway for Psoriatic Arthritis","author":"Salisbury NHS Foundation Trust"},{"key":"key20171003154212591_ref1-bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/IR:32:1-3:045","article-title":"Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology","volume":"32","author":"Bowcock","year":"2005","journal-title":"Immunol Res"},{"key":"key20171003154212591_ref1-bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0022-3859.30334","article-title":"Psoriatic arthritis as a distinct disease entity","volume":"53","author":"Leung","year":"2007","journal-title":"J Postgrad Med"},{"key":"key20171003154212591_ref1-bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3899\/jrheum.090957","article-title":"Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008","volume":"37","author":"Ritchlin","year":"2010","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib23","volume-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","author":"GRAPPA","year":"2016"},{"key":"key20171003154212591_ref1-bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib25","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib26","doi-asserted-by":"crossref","first-page":"839425","DOI":"10.1155\/2012\/839425","article-title":"Measuring disease activity in psoriatic arthritis","volume":"2012","author":"Wong","year":"2012","journal-title":"Int J Rheumatol"},{"key":"key20171003154212591_ref1-bib27","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2011.125","volume-title":"Management of Psoriatic Arthritis from the View of the Dermatologist: Assessment of PsA","author":"Chang","year":"2011"},{"key":"key20171003154212591_ref1-bib28","first-page":"142","article-title":"The assessment of disease activity and outcomes in psoriatic arthritis","volume":"23","author":"Kavanaugh","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key20171003154212591_ref1-bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib30","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2010.140582","article-title":"Psoriatic arthritis: update on pathophysiology, assessment and management","volume":"70","author":"Mease","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib31","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","article-title":"Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis","volume":"160","author":"Haberhauer","year":"2010","journal-title":"Wien Med Wochenschr"},{"issue":"10","key":"key20171003154212591_ref1-bib33","doi-asserted-by":"crossref","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20171003154212591_ref1-bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11595920-000000000-00000","article-title":"Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal","volume":"30","author":"Yang","year":"2012","journal-title":"PharmacoEconomics"},{"key":"key20171003154212591_ref1-bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40273-015-0350-3","article-title":"The clinical and cost effectiveness of ustekinumab for the treatment of psoriatic arthritis: a critique of the evidence","volume":"34","author":"O\u2019Connor","year":"2016","journal-title":"PharmacoEconomics"},{"key":"key20171003154212591_ref1-bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"key20171003154212591_ref1-bib37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2015.09.004","article-title":"Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis","volume":"45","author":"Ungprasert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-011-1790-6","article-title":"Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator","volume":"31","author":"Migliore","year":"2012","journal-title":"Clin Rheumatol"},{"key":"key20171003154212591_ref1-bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Res Synth Methods"},{"key":"key20171003154212591_ref1-bib41","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"key20171003154212591_ref1-bib42","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"key20171003154212591_ref1-bib43","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J Dermatol Sci"},{"key":"key20171003154212591_ref1-bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"key20171003154212591_ref1-bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"key20171003154212591_ref1-bib49","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"key20171003154212591_ref1-bib50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib52","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"key20171003154212591_ref1-bib54","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib55","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib56","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib57","first-page":"977","article-title":"A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20171003154212591_ref1-bib58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"key20171003154212591_ref1-bib59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib61","volume-title":"Psoriatic Arthritis (Active) \u2013 Apremilast (Post DMARDs) [ID682]","author":"National Institute for Health and Care Excellence (NICE)","year":"2015"},{"key":"key20171003154212591_ref1-bib62","first-page":"2853","article-title":"Secukinumab improves skin symptoms and physical functioning compared with ustekinumab in patients with moderate to severe psoriasis with concomitant psoriatic arthritis: subanalysis of a randomized, double blind, parallel-group, active comparator-controlled phase 3b trial","volume":"67","author":"Gottlieb","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20171003154212591_ref1-bib63","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key20171003154212591_ref1-bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","article-title":"Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs","volume":"29","author":"Atteno","year":"2010","journal-title":"Clin Rheumatol"},{"key":"key20171003154212591_ref1-bib65","volume-title":"Evidence Review Group\u2019s Report: Apremilast for Treating Active Psoriatic Arthritis","author":"Corbett","year":"2015"},{"key":"key20171003154212591_ref1-bib66","volume-title":"Evidence Review Group\u2019s Report: Ustekinumab for Treating Active and Progressive Psoriatic Arthritis","author":"Craig","year":"2013"},{"key":"key20171003154212591_ref1-bib67","first-page":"2145","article-title":"Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"67","author":"Gottlieb","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20171003154212591_ref1-bib68","first-page":"S136","article-title":"Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis patients with psoriatic arthritis: a subanalysis of a phase 3, multicenter, double-blind, placebo-controlled study","volume":"65","author":"Gottlieb","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib69","volume-title":"Assessment Report: Otezla","author":"European Medicines Agency","year":"2014"},{"key":"key20171003154212591_ref1-bib70","volume-title":"Evidence Review Group\u2019s Report: Golimumab for the Treatment of Psoriatic Arthritis","author":"Yang","year":"2010"},{"key":"key20171003154212591_ref1-bib71","volume-title":"24 Week Efficacy and 3-Year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis","author":"Novartis Pharmaceuticals","year":"2013"},{"key":"key20171003154212591_ref1-bib72","volume-title":"Efficacy at 24 Weeks with Long Term Safety, Tolerability and Efficacy up to 5 years of Secukinumab in Patients of Active Psoriatic Arthritis","author":"Novartis Pharmaceuticals","year":"2012"},{"key":"key20171003154212591_ref1-bib73","volume-title":"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 years of Secukinumab in Active Psoriatic Arthritis","author":"Novartis Pharmaceuticals","year":"2015"},{"key":"key20171003154212591_ref1-bib74","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"key20171003154212591_ref1-bib75","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib76","first-page":"AB199","article-title":"Effects of golimumab on the dermatologic manifestations of psoriatic arthritis: 5-year results from the long-term extension of the randomized, placebo-controlled, GO-REVEAL study","volume":"68","author":"Krueger","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"key20171003154212591_ref1-bib77","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib78","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib79","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib80","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res"},{"key":"key20171003154212591_ref1-bib81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/annrheumdis-2014-eular.2283","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 2-year results from a phase 3, multicenter, double-blind, placebo-controlled study","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib82","first-page":"39","article-title":"Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1)","volume":"45","author":"Bird","year":"2015","journal-title":"Intern Med J"},{"key":"key20171003154212591_ref1-bib83","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key20171003154212591_ref1-bib84","first-page":"S679","article-title":"Predicting successful long-term treatment with tumour necrosis factor-alpha inhibitors in patients with psoriatic arthritis","volume":"66","author":"Fagerli","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20171003154212591_ref1-bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib86","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib87","doi-asserted-by":"crossref","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"key20171003154212591_ref1-bib88","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.22151","article-title":"Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis","volume":"66","author":"Chen","year":"2014","journal-title":"Arthritis Care Res"},{"key":"key20171003154212591_ref1-bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib91","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"key20171003154212591_ref1-bib92","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/keu252","article-title":"Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO","volume":"53","author":"Glintborg","year":"2014","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib93","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009742.2014.962081","article-title":"Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA","volume":"44","author":"Iannone","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"key20171003154212591_ref1-bib94","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib95","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib96","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2012-202959","article-title":"Tumour necrosis factor \u03b1 blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis","volume":"73","author":"Eder","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib97","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr.20104","article-title":"Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies","volume":"62","author":"Saad","year":"2010","journal-title":"Arthritis Care Res"},{"key":"key20171003154212591_ref1-bib98","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/art.21177","article-title":"Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach","volume":"53","author":"Husted","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib99","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib100","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/rheumatology\/kem270","article-title":"Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis","volume":"46","author":"Morgan","year":"2007","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib101","first-page":"2886","article-title":"Secukinumab safety and tolerability in patients with active psoriatic arthritis and psoriasis: results from a pooled safety analysis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20171003154212591_ref1-bib102","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20171003154212591_ref1-bib103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"key20171003154212591_ref1-bib104","doi-asserted-by":"crossref","DOI":"10.3310\/hta20090","article-title":"Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation","volume":"20","author":"Corbett","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20171003154212591_ref1-bib105","first-page":"S997","article-title":"Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel","volume":"65","author":"Tarp","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib106","first-page":"844","article-title":"Update of certolizumab pegol safety profile: a systematic review and meta-analysis","volume":"37","author":"Capogrosso-Sansone","year":"2014","journal-title":"Drug Saf"},{"key":"key20171003154212591_ref1-bib107","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/08923973.2011.653646","article-title":"Safety of anti-TNF\u03b1 agents in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Girolomoni","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20171003154212591_ref1-bib108","first-page":"ii47","article-title":"The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: results from the BSR biologics register (BSRBR)","volume":"47","author":"Dixon","year":"2008","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2013-205148","article-title":"Psoriatic arthritis treatment and the risk of herpes zoster","volume":"75","author":"Zisman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key20171003154212591_ref1-bib111","volume-title":"NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making","author":"Dias","year":"2011"},{"key":"key20171003154212591_ref1-bib112","volume-title":"Multiple Technology Appraisal. Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease Modifying Antirheumatic Drugs [ID579]. Final Scope","author":"National Institute for Health and Care Excellence (NICE)","year":"2015"},{"key":"key20171003154212591_ref1-bib113","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/009286150804200610","article-title":"How biased are indirect comparisons, particularly when comparisons are made over time in controlled trials?","volume":"42","author":"Julious","year":"2008","journal-title":"Drug Inf J"},{"key":"key20171003154212591_ref1-bib114","volume-title":"NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-regression, Bias and Bias-adjustment","author":"Dias","year":"2011"},{"key":"key20171003154212591_ref1-bib115","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit (with discussion)","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"key20171003154212591_ref1-bib116","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib117","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key20171003154212591_ref1-bib118","doi-asserted-by":"crossref","DOI":"10.3310\/hta15suppl1\/10","article-title":"Golimumab for the treatment of psoriatic arthritis","volume":"15","author":"Yang","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20171003154212591_ref1-bib119","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd edn."},{"key":"key20171003154212591_ref1-bib120","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/j.jval.2014.08.2608","article-title":"Cost-effectiveness of certolizumab pegol in the treatment of active rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis in Romania","volume":"17","author":"Codreanu","year":"2014","journal-title":"Value Health"},{"key":"key20171003154212591_ref1-bib121","doi-asserted-by":"crossref","first-page":"A646","DOI":"10.1016\/j.jval.2015.09.2319","article-title":"Cost\u2013utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece","volume":"18","author":"Tzanetakos","year":"2015","journal-title":"Value Health"},{"key":"key20171003154212591_ref1-bib122","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/ker245","article-title":"Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis","volume":"50","author":"Bojke","year":"2011","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib123","doi-asserted-by":"crossref","first-page":"A648","DOI":"10.1016\/j.jval.2015.09.2325","article-title":"Economic analysis of ustekinumab for psoriatic arthritis in Russia","volume":"18","author":"Einarson","year":"2015","journal-title":"Value Health"},{"key":"key20171003154212591_ref1-bib124","doi-asserted-by":"crossref","first-page":"A446","DOI":"10.1016\/j.jval.2012.08.1392","article-title":"Economic evaluation model of biologic therapies for moderate to severe psoriatic arthritis in Germany","volume":"15","author":"Wang","year":"2012","journal-title":"Value Health"},{"key":"key20171003154212591_ref1-bib125","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20171003154212591_ref1-bib126","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40744-015-0020-0","article-title":"Consensus decision models for biologics in rheumatoid and psoriatic arthritis: recommendations of a multidisciplinary working party","volume":"2","author":"Madan","year":"2015","journal-title":"Rheumatol Ther"},{"key":"key20171003154212591_ref1-bib127","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","article-title":"Guideline for anti-TNF-alpha therapy in psoriatic arthritis","volume":"44","author":"Kyle","year":"2005","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"key20171003154212591_ref1-bib129","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/art.10471","article-title":"Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis","volume":"46","author":"Kobelt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20171003154212591_ref1-bib130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kel147","article-title":"Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis","volume":"45","author":"Bansback","year":"2006","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib131","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1365-2133.2002.04920.x","article-title":"Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment","volume":"147","author":"Hartman","year":"2002","journal-title":"Br J Dermatol"},{"key":"key20171003154212591_ref1-bib132","volume-title":"Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20171003154212591_ref1-bib133","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","article-title":"Cost effectiveness of golimumab for the treatment of active psoriatic arthritis","volume":"13","author":"Cummins","year":"2012","journal-title":"Eur J Health Econ"},{"key":"key20171003154212591_ref1-bib134","volume-title":"Monthly Index of Medical Specialities (MIMS)","author":"Anon","year":"2016"},{"key":"key20171003154212591_ref1-bib135","volume-title":"British National Formulary 2015","author":"Joint Formulary Committee","year":"2015"},{"key":"key20171003154212591_ref1-bib136","volume-title":"Unit Costs of Health and Social Care 2015","author":"Curtis","year":"2015"},{"key":"key20171003154212591_ref1-bib137","volume-title":"NHS Reference Costs 2014 to 2015","author":"Department of Health (DH)","year":"2015"},{"key":"key20171003154212591_ref1-bib138","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/keq182","article-title":"Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK","volume":"49","author":"Poole","year":"2010","journal-title":"Rheumatology"},{"key":"key20171003154212591_ref1-bib139","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2016"},{"key":"key20171003154212591_ref1-bib140","volume-title":"Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis [TA199]","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20171003154212591_ref1-bib141","volume-title":"A Social Tariff for EuroQol: Results from a UK General Population Survey. Centre for Health Economics Discussion Paper 138","author":"Dolan","year":"1995"},{"key":"key20171003154212591_ref1-bib142","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key20171003154212591_ref1-bib143","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/heartjnl-2015-308850","article-title":"Using electronic health records to predict costs and outcomes in stable coronary artery disease","volume":"102","author":"Asaria","year":"2016","journal-title":"Heart"},{"key":"key20171003154212591_ref1-bib144","volume-title":"The Green Book: Appraisal and Evaluation in Central Government","author":"HM Treasury","year":"2013"},{"key":"key20171003154212591_ref1-bib145","volume-title":"National Life Tables, UK: 2013\u20132015","author":"Office for National Statistics","year":"2015"},{"key":"key20171003154212591_ref1-bib146","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09546639909055907","article-title":"Economic impact of psoriasis treatment on the patient and on the National Health Service","volume":"10","author":"Poyner","year":"1999","journal-title":"J Dermatol Treatment"},{"key":"key20171003154212591_ref1-bib147","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00019053-199609020-00003","article-title":"The decision rules of cost-effectiveness analysis","volume":"9","author":"Karlsson","year":"1996","journal-title":"PharmacoEconomics"},{"key":"key20171003154212591_ref1-bib148","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011)","author":"Lefebvre","year":"2011"},{"key":"key20171003154212591_ref1-bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1742-7622-5-13","article-title":"Enhancing access to reports of clinical trials published world-wide \u2013 the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library","volume":"5","author":"Lefebvre","year":"2008","journal-title":"Emerg Themes Epidemiol"},{"key":"key20171003154212591_ref1-bib150","volume-title":"Search Strategies for DARE","author":"Centre for Reviews and Dissemination","year":"2015"},{"key":"key20171003154212591_ref1-bib151","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"key20171003154212591_ref1-bib152","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/11533010-000000000-00000","article-title":"Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis","volume":"28","author":"Adams","year":"2010","journal-title":"PharmacoEconomics"},{"key":"key20171003154212591_ref1-bib153","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jval.2011.03.002","article-title":"The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort","volume":"14","author":"Adams","year":"2011","journal-title":"Value Health"},{"key":"key20171003154212591_ref1-bib154","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/03009740903468982","article-title":"Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey","volume":"39","author":"Brodszky","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"key20171003154212591_ref1-bib155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.reuma.2013.05.006","article-title":"Health-related quality of life in psoriatic arthritis patients in Spain","volume":"10","author":"Gratac\u00f3s","year":"2014","journal-title":"Reumatol Clin"},{"key":"key20171003154212591_ref1-bib156","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3899\/jrheum.120782","article-title":"Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study","volume":"40","author":"Leung","year":"2013","journal-title":"J Rheumatol"},{"key":"key20171003154212591_ref1-bib157","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11136-010-9651-3","article-title":"Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept","volume":"19","author":"Picchianti-Diamanti","year":"2010","journal-title":"Qual Life Res"},{"key":"key20171003154212591_ref1-bib158","first-page":"31","article-title":"Golimumab in the PsA treatment","volume":"24","author":"Stolfa","year":"2010","journal-title":"Rheumatologia"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21560\/hta21560.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002741","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21560\/hta21560.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2011095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:26:37Z","timestamp":1750897597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta21560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":158,"journal-issue":{"issue":"56","published-online":{"date-parts":[[2017,10]]}},"alternative-id":["10.3310\/hta21560"],"URL":"https:\/\/doi.org\/10.3310\/hta21560","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}